Pet Scan Brain

Quitting smoking may be down to our genes

CARDIFF: A variation of a brain protein may make it harder for some individuals to quit smoking than others, according to new findings that may lead to the development of treatments that increase a quitter's chance of success.

The study, published in the current issue of Proceedings of the National Academy of Science , suggests that the difficulties some people experience when trying to quit may be due to the amount of 'mu opioid' receptors in his or her brain. A commonly occurring form of a gene for the receptor is tied to the severity of nicotine dependence, withdrawal, and relapse.

"For the first time we've identified a mechanism that explains why people with a particular genetic background may be more prone to relapse when they try to quit smoking," said senior author Caryn Lerman of the University of Pennsylvania in the U.S. "We've connected the dots between the genes, the brain, and the behaviour."

Connecting the dots

Although multiple mechanisms in the brain have already been implicated in addiction, a growing body of evidence points to the endogenous opioid system and the mu-opioid receptor (MOR) in particular. These act to mediate the reinforcing effects of addictive drugs, including nicotine.

The researchers found that a variation in an individual's genetic makeup can result in an increase in the amount of receptors that are associated with rewards and emotions.

Specifically, smokers who had two copies of the common 'wild-type' version of the mu opioid receptor gene had significantly more receptors available, compared to smokers who inherited just one variant of the mu opioid receptor gene.

"These smokers have a greater number of mu opioid receptors that respond to brain chemicals such as beta-endorphin which are released by nicotine. And having more available receptors of this type appears to be related to finding nicotine more rewarding," said Lerman.

Increased Levels and Increased Reward

Lerman and colleagues used a brain imaging technique, called positron emission tomography (PET), to measure the numbers of mu opioid brain receptors in the study participants.

When the participants reported the degree of satisfaction gained from either a normal cigarette or one that lacked nicotine, no difference was found between them. However, there was an association between greater reported reward and more receptor expression in the participants who carried at least one copy of the genetic variant.

New Imaging procedure Identifies persons At possibility For ...

— UCLA scientists utilised revolutionary brain scan engineering to display the irregular brain protein deposits that outline Alzheimer’s disorder is usually detected in gentle cognitive impairment — a problem that raises the possibility for creating Alzheimer’s disorder and influences fifteen to twenty million us residents. The examine is going to be revealed inside Dec. 21 New England Journal of medication.

Scientists are inside early phases of identifying biomarkers inside blood and spinal fluid to support with Alzheimer’s prognosis, but this new examine could be the to begin with to report a actual time "window in to the brain" that identifies the two of your big irregular deposits of your disorder in residing persons who might not produce Alzheimer’s for a long time to arrive. The scientists utilised positron emission tomography (PET) imaging having a smaller molecule invented at UCLA that binds for the irregular proteins — amyloid plaques and tangles — that might bring about the disorder. formerly only an autopsy could decide these deposits and verify a definitive prognosis.

Study success uncovered the new process was in a position to track disorder progression around a two-year time period and was a lot more helpful in differentiating sufferers with Alzheimer’s disorder and gentle cognitive impairment from ordinary examine topics when in contrast to standard imaging tactics. scientists are functioning with Siemens health care to get started a medical trial utilizing this new molecular marker to be able to attain meals and Drug Administration (FDA) approval to ensure it is going to be accessible inside potential for use by doctors with their sufferers.

"The examine suggests that we might now have a whole new diagnostic instrument for detecting pre-Alzheimer’s circumstances to support us discover people at possibility, maybe a long time ahead of signs or symptoms turn into apparent," claimed Dr. Gary smaller, Parlow-Solomon Professor on getting older, lead examine writer along with a professor using the Semel Institute for Neuroscience and Human habits at UCLA. "This imaging engineering might also enable us to check novel drug therapies and handle disorder progression around time, maybe guarding the brain ahead of injury takes place."

The examine incorporated 83 volunteers aged 49 to 84. primarily based on cognitive screening, 25 sufferers had Alzheimer’s disorder, 28 had gentle cognitive impairment and thirty ended up ordinary controls.

Brain imaging using PET

Methods of Cancer Diagnosis, Therapy, and Prognosis, Brain Cancer

Psychology

The Encyclopedia of Alzheimer's Disease

Nutrition and diagnosis-related care